Muhammad Inam
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Muhammad Inam has a total of 80 co-authors. Here are the top co-authors by number of shared publications:
Muhammad Hayat
School of Medicine, Qilu Institute of Technology
4 shared publicationsMuhammad Jamshed
Northwest School of Medicine
4 shared publications- Abuzar Osman
Department of Basic Health Sciences, College of Applied Medical Sciences, Qassim University
3 shared publications - Hamid Khan
Institute of Brain Science and Brain-Inspired Research, Shandong First Medical University and Shandong Academy of Medical Sciences
3 shared publications - Wenjie Chen
Guangdong Province and NMPA and State Key Laboratory of Respiratory Disease, School of Pharmaceutical Sciences; Department of Emergency, Guangzhou Institute of Emergency Medicine, The Second Affiliated Hospital, Guangzhou Medical University, Guangzhou, People’s Republic Of China
3 shared publications - Chuanshan Xu
The NMPA and State Key Laboratory of Respiratory Disease, School of Pharmaceutical Sciences, Department of Emergency, The Second Affiliated Hospital, Guangzhou Medical University, Guangzhou, 511436, PR China
2 shared publications
Latest Publications
- Open Access
- 3 November 2026
- Published by Frontiers Media SA in Frontiers in Chemistry
- Vol. 14, 1965408
The advanced biopharmaceutical application of cocrystal
Poor aqueous solubility remains a major challenge in drug development, particularly for Biopharmaceutics Classification System (BCS) class II drugs, whose absorption is limited by solubility and dissolution rate. For BCS class IV drugs, which are additionally restricted by permeability, the benefit of solubility enhancement is less predictable. Pharmaceutical cocrystals are a promising and innovative solid-state approach to improve the biopharmaceutical properties of active pharmaceutical ingredients (APIs) without changing their intrinsic chemical structure and pharmacological identity. This review systematically examines the basic design concepts, the wide range of therapeutic applications, and the mechanism of dissolution enhancement and bioavailability improvement of cocrystals. We discuss the integration of cocrystals into synergistic combination therapies, stimuli-responsive smart delivery systems, and advanced nanoscale formulations that enable targeted and controlled drug release. Despite this, there are significant challenges remaining, such as physiological instability in the gastrointestinal tract, manufacturing scalability and reproducibility, rational coformer selection strategies, and regulatory uncertainty exacerbated by sparse pharmacokinetic information and a lack of understanding regarding cocrystal biological interactions at a molecular level. Bringing cocrystal-based formulations to clinical use will take joint, multidisciplinary, and solution-driven efforts across the disciplines of pharmaceutical sciences, materials chemistry, regulatory science, and clinical pharmacology. Finally, pharmaceutical cocrystals represent a promising platform to address solubility restrictions, with growing evidence, predominantly preclinical, of improved therapeutic performance for poorly soluble drugs.
- 3 November 2026
- Published by Frontiers Media SA in Frontiers in Chemistry
- Vol. 14, 1965408
Open AccessThe advanced biopharmaceutical application of cocrystal
Poor aqueous solubility remains a major challenge in drug development, particularly for Biopharmaceutics Classification System (BCS) class II drugs, whose absorption is limited by solubility and dissolution rate. For BCS class IV drugs, which are additionally restricted by permeability, the benefit of solubility enhancement is less predictable. Pharmaceutical cocrystals are a promising and innovative solid-state approach to improve the biopharmaceutical properties of active pharmaceutical ingredients (APIs) without changing their intrinsic chemical structure and pharmacological identity. This review systematically examines the basic design concepts, the wide range of therapeutic applications, and the mechanism of dissolution enhancement and bioavailability improvement of cocrystals. We discuss the integration of cocrystals into synergistic combination therapies, stimuli-responsive smart delivery systems, and advanced nanoscale formulations that enable targeted and controlled drug release. Despite this, there are significant challenges remaining, such as physiological instability in the gastrointestinal tract, manufacturing scalability and reproducibility, rational coformer selection strategies, and regulatory uncertainty exacerbated by sparse pharmacokinetic information and a lack of understanding regarding cocrystal biological interactions at a molecular level. Bringing cocrystal-based formulations to clinical use will take joint, multidisciplinary, and solution-driven efforts across the disciplines of pharmaceutical sciences, materials chemistry, regulatory science, and clinical pharmacology. Finally, pharmaceutical cocrystals represent a promising platform to address solubility restrictions, with growing evidence, predominantly preclinical, of improved therapeutic performance for poorly soluble drugs.
- Open Access
- 30 October 2026
- Published by Frontiers Media SA in Frontiers in Veterinary Science
- Vol. 13, 1962397
Hantaviruses at the human-animal-environment interface: a One Health review of rodent reservoirs, surveillance, and preparedness
Hantaviruses maintained in small mammals cause hemorrhagic fever with renal syndrome and hantavirus cardiopulmonary syndrome. Exposure usually arises from contact with infected rodent excreta, so prevention depends on understanding reservoir ecology, human activities, and the settings in which they intersect. This structured narrative review synthesizes evidence on host relationships, exposure, clinical and laboratory recognition, genomic investigation, and One Health surveillance across several regions. We propose three risk-proportionate tiers: baseline readiness where evidence is sparse, enhanced investigation after a credible signal, and sustained integrated surveillance where transmission is established. Five shared functions are scaled across tiers: reservoir sampling, clinical recognition and referral testing, molecular characterization, occupational and environmental assessment, and cross-sector data review. Published outbreaks in Croatia and long-running surveillance in Panama illustrate how the decision logic could be applied, while the 2026 Andes virus cruise-ship event highlights the need for diagnostics and contact management. The framework provides a practical way to plan surveillance with limited resources, but its triggers, workload, and impact remain to be evaluated prospectively.
- 30 October 2026
- Published by Frontiers Media SA in Frontiers in Veterinary Science
- Vol. 13, 1962397
Open AccessHantaviruses at the human-animal-environment interface: a One Health review of rodent reservoirs, surveillance, and preparedness
Hantaviruses maintained in small mammals cause hemorrhagic fever with renal syndrome and hantavirus cardiopulmonary syndrome. Exposure usually arises from contact with infected rodent excreta, so prevention depends on understanding reservoir ecology, human activities, and the settings in which they intersect. This structured narrative review synthesizes evidence on host relationships, exposure, clinical and laboratory recognition, genomic investigation, and One Health surveillance across several regions. We propose three risk-proportionate tiers: baseline readiness where evidence is sparse, enhanced investigation after a credible signal, and sustained integrated surveillance where transmission is established. Five shared functions are scaled across tiers: reservoir sampling, clinical recognition and referral testing, molecular characterization, occupational and environmental assessment, and cross-sector data review. Published outbreaks in Croatia and long-running surveillance in Panama illustrate how the decision logic could be applied, while the 2026 Andes virus cruise-ship event highlights the need for diagnostics and contact management. The framework provides a practical way to plan surveillance with limited resources, but its triggers, workload, and impact remain to be evaluated prospectively.
- Open Access
- 26 October 2026
- Published by Frontiers Media SA in Frontiers in Pharmacology
- Vol. 17, 1953410
Nanomaterials for endometriosis: a multimodal strategy integrating targeted delivery, immunomodulation, and physical ablation
Endometriosis is a chronic inflammatory condition for which existing treatments, mainly hormonal therapy and surgical intervention, remain insufficient. These approaches are often limited by high recurrence rates, significant side effects, and an inability to effectively target underlying disease mechanisms. This review outlines emerging mechanism-oriented therapeutic strategies that combine targeted drug delivery, immunomodulation, and physical ablation. Advanced delivery systems, such as Lipid nanoparticle polymeric carriers, and nanomicelles, enable selective accumulation of therapeutic agents at endometriotic lesions, improving efficacy while minimizing systemic toxicity. Immunomodulatory strategies pursue to re-establish immune balance by enhancing immune surveillance, driving macrophage polarization toward anti-inflammatory states, and suppressing pro-inflammatory signaling, often through nanocarrier-enabled localized delivery. Furthermore, physical ablation techniques including gold (Au) NPs-mediated photothermal therapy and magnetic hyperthermia offer minimally invasive approaches for precise lesion elimination while preserving adjacent healthy tissues. Collectively, integrating these strategies may advance preclinical efforts to improve disease management, patient stratification, and potentially fertility outcomes, although clinical validation is still required. Despite ongoing challenges in clinical translation, the convergence of nanotechnology, immunology and interventional therapy marks a conceptual shift away from symptom-centered management toward investigational strategies that, pending clinical validation, may confer disease-modifying potential in endometriosis.
- 26 October 2026
- Published by Frontiers Media SA in Frontiers in Pharmacology
- Vol. 17, 1953410
Open AccessNanomaterials for endometriosis: a multimodal strategy integrating targeted delivery, immunomodulation, and physical ablation
Endometriosis is a chronic inflammatory condition for which existing treatments, mainly hormonal therapy and surgical intervention, remain insufficient. These approaches are often limited by high recurrence rates, significant side effects, and an inability to effectively target underlying disease mechanisms. This review outlines emerging mechanism-oriented therapeutic strategies that combine targeted drug delivery, immunomodulation, and physical ablation. Advanced delivery systems, such as Lipid nanoparticle polymeric carriers, and nanomicelles, enable selective accumulation of therapeutic agents at endometriotic lesions, improving efficacy while minimizing systemic toxicity. Immunomodulatory strategies pursue to re-establish immune balance by enhancing immune surveillance, driving macrophage polarization toward anti-inflammatory states, and suppressing pro-inflammatory signaling, often through nanocarrier-enabled localized delivery. Furthermore, physical ablation techniques including gold (Au) NPs-mediated photothermal therapy and magnetic hyperthermia offer minimally invasive approaches for precise lesion elimination while preserving adjacent healthy tissues. Collectively, integrating these strategies may advance preclinical efforts to improve disease management, patient stratification, and potentially fertility outcomes, although clinical validation is still required. Despite ongoing challenges in clinical translation, the convergence of nanotechnology, immunology and interventional therapy marks a conceptual shift away from symptom-centered management toward investigational strategies that, pending clinical validation, may confer disease-modifying potential in endometriosis.
- Open Access
- 2 October 2026
- Published by Taylor & Francis in Human Vaccines & Immunotherapeutics
- Vol. 22 (1)
Engineered nanovaccines for prophylactic and therapeutic immunotherapy against cancer and infectious disease
Cancer and infectious diseases remain threat to the global public health system, and there is a pending need to develop more effective immunotherapeutic and prophylactic agents.1 While there have b...
- 2 October 2026
- Published by Taylor & Francis in Human Vaccines & Immunotherapeutics
- Vol. 22 (1)
Open AccessEngineered nanovaccines for prophylactic and therapeutic immunotherapy against cancer and infectious disease
Cancer and infectious diseases remain threat to the global public health system, and there is a pending need to develop more effective immunotherapeutic and prophylactic agents.1 While there have b...
- 10 September 2026
- Published by Wiley in Advanced Therapeutics
- Vol. 9 (9)
Carbon Dots in Biopharmaceuticals: Advances in Theranostics, Drug Delivery, Antimicrobial Therapy, and Tissue Regeneration
Carbon dots (CDs) are fluorescent carbon nanoparticles (NPs) that have developed as a transformative nanoplatform in biopharmaceuticals. Distinguished from conventional quantum dots, CDs offer a unique combination of properties such as tunable photoluminescence, aqueous stability, facile surface chemistry, and demonstrated biocompatibility. These features make them ideal nanotheranostic agents for integrating diagnostics and therapy. This review summarizes their progression from tailored synthesis to preclinical applications. We examine their roles as probes and stimuli‐responsive nanocarriers for biosensing, bioimaging, drug delivery, and integrated theranostics platforms. We critically evaluate their pharmacokinetics, biodistribution, and safety, while addressing translational challenges in standardization and scalable manufacturing. Future perspectives on atomic‐level development are outlined, charting a course toward clinical translation.
- 10 September 2026
- Published by Wiley in Advanced Therapeutics
- Vol. 9 (9)
Carbon Dots in Biopharmaceuticals: Advances in Theranostics, Drug Delivery, Antimicrobial Therapy, and Tissue Regeneration
Carbon dots (CDs) are fluorescent carbon nanoparticles (NPs) that have developed as a transformative nanoplatform in biopharmaceuticals. Distinguished from conventional quantum dots, CDs offer a unique combination of properties such as tunable photoluminescence, aqueous stability, facile surface chemistry, and demonstrated biocompatibility. These features make them ideal nanotheranostic agents for integrating diagnostics and therapy. This review summarizes their progression from tailored synthesis to preclinical applications. We examine their roles as probes and stimuli‐responsive nanocarriers for biosensing, bioimaging, drug delivery, and integrated theranostics platforms. We critically evaluate their pharmacokinetics, biodistribution, and safety, while addressing translational challenges in standardization and scalable manufacturing. Future perspectives on atomic‐level development are outlined, charting a course toward clinical translation.
- 6 March 2026
- Published by Wiley in Journal of the Chinese Chemical Society
- Vol. 73 (4) , 614-632
The transformative role of metal‐based nanoparticles in modern biomedicine
Metal‐based nanoparticles (MNPs) are composed of metals, such as gold (Au), silver (Ag), zinc (Zn), iron (Fe), and manganese (Mn), and are utilized across various biomedical applications. The unique physicochemical profile of MNPs, characterized by tunable size, a high surface‐area‐to‐volume ratio, and distinctive optical, magnetic, and catalytic properties, facilitates applications impossible for bulk materials or standard molecular therapeutics. This review examines recent developments and modifications in the functional properties of MNPs, with particular emphasis on potentially groundbreaking applications, including NPs containing Au, Ag, Fe, and other emerging MNPs. Their applications in nanomedicine, specifically in cancer detection and treatment, wound healing, antimicrobial therapy, imaging, as well as liver and fibrosis treatment, are thoroughly discussed. Factors influencing the future clinical utility of these NPs include their interactions within the human body and the relative ease of their production. MNPs hold significant promise for advancing sophisticated diagnostic and therapeutic techniques. The review also delineates prospective future directions in this field.
- 6 March 2026
- Published by Wiley in Journal of the Chinese Chemical Society
- Vol. 73 (4) , 614-632
The transformative role of metal‐based nanoparticles in modern biomedicine
Metal‐based nanoparticles (MNPs) are composed of metals, such as gold (Au), silver (Ag), zinc (Zn), iron (Fe), and manganese (Mn), and are utilized across various biomedical applications. The unique physicochemical profile of MNPs, characterized by tunable size, a high surface‐area‐to‐volume ratio, and distinctive optical, magnetic, and catalytic properties, facilitates applications impossible for bulk materials or standard molecular therapeutics. This review examines recent developments and modifications in the functional properties of MNPs, with particular emphasis on potentially groundbreaking applications, including NPs containing Au, Ag, Fe, and other emerging MNPs. Their applications in nanomedicine, specifically in cancer detection and treatment, wound healing, antimicrobial therapy, imaging, as well as liver and fibrosis treatment, are thoroughly discussed. Factors influencing the future clinical utility of these NPs include their interactions within the human body and the relative ease of their production. MNPs hold significant promise for advancing sophisticated diagnostic and therapeutic techniques. The review also delineates prospective future directions in this field.
- Open Access
- 1 November 2024
- Published by MDPI AG in Pharmaceutics
- Vol. 16 (11) , 1408
Optimizing Antitumor Effect of Triple-Negative Breast Cancer via Rosmarinic Acid–β-Cyclodextrin Inclusion Complex
Background: Rosmarinic acid (ROS) has gained notable attention for its anticancer potential; however, its limited aqueous solubility hinders its effective delivery and application in pharmaceutical formulations. Methods: To overcome this limitation, an inclusion complex of ROS with β-cyclodextrin (β-CD) was prepared using the recrystallization method. The resultant ROS–β-CD complex was comprehensively characterized by powder X-ray diffraction (PXRD), differential scanning calorimetry (DSC), Fourier transform infrared spectroscopy (FT-IR), and scanning electron microscopy (SEM). Results: The ROS–β-CD complex showed a significant improvement in the solubility and dissolution profile of ROS, underscoring its potential for enhanced bioavailability and therapeutic efficacy in pharmaceutical applications. In vitro assays were performed to assess the effects on cell viability, proliferation, apoptotic pathways, and 3D spheroid tumor models. Conclusions: The results demonstrated that ROS–β-CD exhibited superior anticancer properties compared to free ROS, effectively reducing the viability and proliferation of the MD-MBA-231 cell line and inducing apoptosis. This research signifies a substantial advancement in developing therapeutic strategies for TNBC, leveraging the distinct properties of the ROS–β-CD inclusion complex.
- 1 November 2024
- Published by MDPI AG in Pharmaceutics
- Vol. 16 (11) , 1408
Open AccessOptimizing Antitumor Effect of Triple-Negative Breast Cancer via Rosmarinic Acid–β-Cyclodextrin Inclusion Complex
Background: Rosmarinic acid (ROS) has gained notable attention for its anticancer potential; however, its limited aqueous solubility hinders its effective delivery and application in pharmaceutical formulations. Methods: To overcome this limitation, an inclusion complex of ROS with β-cyclodextrin (β-CD) was prepared using the recrystallization method. The resultant ROS–β-CD complex was comprehensively characterized by powder X-ray diffraction (PXRD), differential scanning calorimetry (DSC), Fourier transform infrared spectroscopy (FT-IR), and scanning electron microscopy (SEM). Results: The ROS–β-CD complex showed a significant improvement in the solubility and dissolution profile of ROS, underscoring its potential for enhanced bioavailability and therapeutic efficacy in pharmaceutical applications. In vitro assays were performed to assess the effects on cell viability, proliferation, apoptotic pathways, and 3D spheroid tumor models. Conclusions: The results demonstrated that ROS–β-CD exhibited superior anticancer properties compared to free ROS, effectively reducing the viability and proliferation of the MD-MBA-231 cell line and inducing apoptosis. This research signifies a substantial advancement in developing therapeutic strategies for TNBC, leveraging the distinct properties of the ROS–β-CD inclusion complex.
- Open Access
- 22 October 2024
- Published by Society of Eminent Biological Scientists in International Journal of Applied and Experimental Biology
Biofabricated silver nanoparticles from Calotropis procera: A potential antimicrobial solution against pathogenic bacteria
Calotropis procera has the potential as a traditional medicinal plant that offers a diverse array of healing treatments. It was used in conventional medicine to remedy several ailments, including diarrhea and snakebites. This study examines the antibacterial properties of silver nanoparticles derived from the floral and latex components of C. procera. The nanoparticles were tested for their effectiveness against Gram-negative and Gram-positive bacterial strains. For characterization, the synthesized nanoparticles underwent thorough analysis using UV spectroscopy, fourier-transform infrared spectroscopy (FTIR), X-ray diffraction (XRD), and scanning electron microscopy (SEM). After the reduction process, the FTIR analysis revealed that some functional biomolecules found in plants form a coating on the nanoparticles, serving as organic agents that stabilize the nanoparticles. The size of nanoparticles analyzed with SEM falls in the 30 to 130 nm range. Furthermore, the synthesized silver nanoparticles were tested as antimicrobial agents against Escherichia coli, Bacillus subtilis, Staphylococcus aureus, and Pseudomonas aeruginosa, well-known microorganisms that can produce ulceration phases and severe health consequences. After a comprehensive examination, it was found that the silver nanoparticles have significant antibacterial effectiveness, particularly against S. aureus, a primary bacterium responsible for causing different ailments. The remarkable antibacterial efficacy of the silver nanoparticles synthesized in an environment-friendly manner underscores its potential applications in combating the evolution of antibiotic-resistant strains.
- 22 October 2024
- Published by Society of Eminent Biological Scientists in International Journal of Applied and Experimental Biology
Open AccessBiofabricated silver nanoparticles from Calotropis procera: A potential antimicrobial solution against pathogenic bacteria
Calotropis procera has the potential as a traditional medicinal plant that offers a diverse array of healing treatments. It was used in conventional medicine to remedy several ailments, including diarrhea and snakebites. This study examines the antibacterial properties of silver nanoparticles derived from the floral and latex components of C. procera. The nanoparticles were tested for their effectiveness against Gram-negative and Gram-positive bacterial strains. For characterization, the synthesized nanoparticles underwent thorough analysis using UV spectroscopy, fourier-transform infrared spectroscopy (FTIR), X-ray diffraction (XRD), and scanning electron microscopy (SEM). After the reduction process, the FTIR analysis revealed that some functional biomolecules found in plants form a coating on the nanoparticles, serving as organic agents that stabilize the nanoparticles. The size of nanoparticles analyzed with SEM falls in the 30 to 130 nm range. Furthermore, the synthesized silver nanoparticles were tested as antimicrobial agents against Escherichia coli, Bacillus subtilis, Staphylococcus aureus, and Pseudomonas aeruginosa, well-known microorganisms that can produce ulceration phases and severe health consequences. After a comprehensive examination, it was found that the silver nanoparticles have significant antibacterial effectiveness, particularly against S. aureus, a primary bacterium responsible for causing different ailments. The remarkable antibacterial efficacy of the silver nanoparticles synthesized in an environment-friendly manner underscores its potential applications in combating the evolution of antibiotic-resistant strains.
- 16 September 2024
- Published by Wiley in Journal of the Chinese Chemical Society
- Vol. 71 (11) , 1358-1367
Engineered metal nanoparticles for precision drug delivery: Pioneering the future of medicine: Mini review
Metal nanoparticles (NPs) have emerged as crucial components in precision drug delivery, presenting innovative opportunities to significantly enhance therapeutic efficacy and targeting accuracy. This review investigates recent developments in the engineering of metal NPs, emphasizing their distinctive properties and novel applications in drug delivery systems. A comprehensive analysis is performed on gold, silver, iron, and zinc oxide NPs, emphasizing their exceptional physicochemical properties and enhanced drug‐loading capacities. These features collectively enable the development and implementation of targeted and controlled drug delivery systems, indicating a new era of advanced therapeutic approaches. This review article accomplishes this by reflecting on the transformative potential of metal NPs, envisioning heightened efficacy, minimized side effects, and improved patient outcomes within the dynamic landscape of drug delivery platforms.
- 16 September 2024
- Published by Wiley in Journal of the Chinese Chemical Society
- Vol. 71 (11) , 1358-1367
Engineered metal nanoparticles for precision drug delivery: Pioneering the future of medicine: Mini review
Metal nanoparticles (NPs) have emerged as crucial components in precision drug delivery, presenting innovative opportunities to significantly enhance therapeutic efficacy and targeting accuracy. This review investigates recent developments in the engineering of metal NPs, emphasizing their distinctive properties and novel applications in drug delivery systems. A comprehensive analysis is performed on gold, silver, iron, and zinc oxide NPs, emphasizing their exceptional physicochemical properties and enhanced drug‐loading capacities. These features collectively enable the development and implementation of targeted and controlled drug delivery systems, indicating a new era of advanced therapeutic approaches. This review article accomplishes this by reflecting on the transformative potential of metal NPs, envisioning heightened efficacy, minimized side effects, and improved patient outcomes within the dynamic landscape of drug delivery platforms.
- Open Access
- 30 November 2023
- Published by MDPI AG in Pharmaceutics
- Vol. 15 (12) , 2713
Cocrystallization of Gefitinib Potentiate Single-Dose Oral Administration for Lung Tumor Eradication via Unbalancing the DNA Damage/Repair
Gefitinib (GEF) is a clinical medication for the treatment of lung cancer targeting the epidermal growth factor receptor (EGFR). However, its efficacy is remarkably limited by low solubility and dissolution rates. In this study, two cocrystals of GEF with co-formers were successfully synthesized using the recrystallization method characterized via Powder X-ray Diffraction, Fourier Transform Infrared Spectroscopy, and 2D Nuclear Overhauser Effect Spectroscopy. The solubility and dissolution rates of cocrystals were found to be two times higher than those of free GEF. In vitro cytotoxicity studies revealed that the cocrystals enhanced the inhibition of cell proliferation and apoptosis in A549 and H1299 cells compared to free GEF. In mouse models, GEF@TSBO demonstrated targeted, safe, and effective antitumor activity with only one-dose administration. Mechanistically, the GEF cocrystals were shown to increase the cellular levels of damaged DNA, while potentially downregulating PARP, thereby impairing the DNA repair machinery and leading to an imbalance between DNA damage and restoration. These findings suggest that the cocrystallization of GEF could serve as a promising adjunct to significantly enhance the physicochemical and biopharmaceutical performance for lung cancer treatment, providing a facial strategy to improve GEF anticancer efficiency with high bioavailability that can be orally administrated with only one dose.
- 30 November 2023
- Published by MDPI AG in Pharmaceutics
- Vol. 15 (12) , 2713
Open AccessCocrystallization of Gefitinib Potentiate Single-Dose Oral Administration for Lung Tumor Eradication via Unbalancing the DNA Damage/Repair
Gefitinib (GEF) is a clinical medication for the treatment of lung cancer targeting the epidermal growth factor receptor (EGFR). However, its efficacy is remarkably limited by low solubility and dissolution rates. In this study, two cocrystals of GEF with co-formers were successfully synthesized using the recrystallization method characterized via Powder X-ray Diffraction, Fourier Transform Infrared Spectroscopy, and 2D Nuclear Overhauser Effect Spectroscopy. The solubility and dissolution rates of cocrystals were found to be two times higher than those of free GEF. In vitro cytotoxicity studies revealed that the cocrystals enhanced the inhibition of cell proliferation and apoptosis in A549 and H1299 cells compared to free GEF. In mouse models, GEF@TSBO demonstrated targeted, safe, and effective antitumor activity with only one-dose administration. Mechanistically, the GEF cocrystals were shown to increase the cellular levels of damaged DNA, while potentially downregulating PARP, thereby impairing the DNA repair machinery and leading to an imbalance between DNA damage and restoration. These findings suggest that the cocrystallization of GEF could serve as a promising adjunct to significantly enhance the physicochemical and biopharmaceutical performance for lung cancer treatment, providing a facial strategy to improve GEF anticancer efficiency with high bioavailability that can be orally administrated with only one dose.